Высококачественный порошок сермаглутида Semaglutide CAS 910463-68-2

Amy | Sales manager

ANHUI SHENGZHIKAI BIOTECHNOLOGY CO.,LTD.

Phone:+86 19155187336(whatsapp)

Email:shengzhikai3@shengzhikai.com

Address: 903, block B, Fortune Plaza, Luyang District, Hefei City, Anhui Province

Product Description

 Purity 99% Sermaglutide Powder CAS 910463-68-2/ tirzepatide CAS 2023788-19-2 Wholesale Price

Product Description

Use of Semaglutide acetate salt
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes.

Detailed Product Information

Product Name :Tirzepatide

Trade Name: M-ounjaro

CAS No.:2023788-19-2

Purity : 98% HPLC

Appearance:  Lyophilized Powder

Typical use: weight loss peptides

Shelf Life :2 years

Storage:Refrigeration keep dry and away from light.

Description:

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. 

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid moiety. Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions in the glycated hemoglobin level and weight at 26 weeks.

Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2 diabetes at doses up to 1 mg. In trials involving patients who received semaglutide, the mean reductions in the glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in body weight have been reported to be as high as 6.5 kg.

We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg with those of semaglutide at a dose of 1 mg in patients with type 2 diabetes that had been inadequately controlled with metformin monotherapy.

R-ybelsus (semaglutide) is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

R-ybelsus is usually given after other diabetes medicines have been tried without success.

The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release.

Weekly semaglutide 2.4 mg (W-egovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide is indicated for chronic weight management in adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as type 2 diabetes or hypertension, or in adults with a BMI of at least 30 kg/m²

Semaglutide 1 mg injection (O-zempic) was first approved as a treatment for type 2 diabetes in 2017.

Safety and efficacy of semaglutide 2.4 mg was assessed in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials, including 16 weeks of dose increases, and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients assigned semaglutide either continued treatment or switched to a placebo

Semaglutide 2.4 mg should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists or other products intended for weight loss, including prescription drugs, over-the-counter drugs and herbal products, according to the release. Semaglutide 2.4 mg has not been studied in patients with a history of pancreatitis.

This is a once-weekly injectable, which is more tolerable way of managing obesity vs. other treatments. The STEP study data showed semaglutide 2.4 mg crosses the magic threshold of 10% weight loss for many people who received it. This is another tool that will allow clinicians to better manage obesity.

hot sale